Contact
searchSearch
HMP Global
Podcasts

Has the PPI Ship Sailed?

06/15/2018

 

 

 

Dr Jamie Koufman, founder and director of the Voice Institute of New York and one of the world's leading authorities on acid reflux, discusses proton pump inhibitors—their adverse effects, alternatives, and more.

 

For more information about PPI use, visit our Medical Resource Center here.

Sign up for our e-Newsletters

Gastroenterology Newsletter

News

News
Colonoscopy After Diverticulitis Usually Unnecessary
11/14/2024
In colonoscopies performed solely for diverticulitis, the CRC prevalence was just 0.17%, the study found.
In colonoscopies performed solely for diverticulitis, the CRC prevalence was just 0.17%, the study found.
In colonoscopies performed...
11/14/2024
Gastroenterology
News
Upper Gl Mucosal Damage Associated With Parkinson's Disease
10/18/2024
Upper gastrointestinal (GI) mucosal damage was associated with elevated risk of developing Parkinson's disease.
Upper gastrointestinal (GI) mucosal damage was associated with elevated risk of developing Parkinson's disease.
Upper gastrointestinal (GI)...
10/18/2024
Gastroenterology
News
Vonoprozan Compared to PPIs for Peptic Ulcer Rebleeding Prevention
10/18/2024
Vonoprazan offers an effective alternative treatment to intravenous proton pump inhibitors for prevention of rebleeding among patients with high-risk peptic ulcers, researchers found.
Vonoprazan offers an effective alternative treatment to intravenous proton pump inhibitors for prevention of rebleeding among patients with high-risk peptic ulcers, researchers found.
Vonoprazan offers an effective...
10/18/2024
Gastroenterology
News
NAFLD or MASLD? Research Looks at Concordance of Criteria
10/18/2024
New nomenclature shows strong applicability in real-world clinical settings.
New nomenclature shows strong applicability in real-world clinical settings.
New nomenclature shows strong...
10/18/2024
Gastroenterology
News
Liver Histology Impact on Long-Term Clinical Outcomes in MASH
10/18/2024
Results showed that a lower fibrosis stage (F0–1) was associated with a significantly reduced risk of cirrhosis and liver-related outcomes compared to patients with advanced fibrosis (F4).
Results showed that a lower fibrosis stage (F0–1) was associated with a significantly reduced risk of cirrhosis and liver-related outcomes compared to patients with advanced fibrosis (F4).
Results showed that a lower...
10/18/2024
Gastroenterology
News
AI-Enabled Electrocardiogram Shows Promise in Predicting MASLD
10/18/2024
Researchers explored the use of an artificial intelligence model to detect metabolic dysfunction–associated steatotic liver disease.
Researchers explored the use of an artificial intelligence model to detect metabolic dysfunction–associated steatotic liver disease.
Researchers explored the use of...
10/18/2024
Gastroenterology
News
New Age Recommendation Yields Uptake in CRC Screening But Disparities Found
10/18/2024
Income level and location drove variations in rates of increase, authors of a retrospective cohort study found.
Income level and location drove variations in rates of increase, authors of a retrospective cohort study found.
Income level and location drove...
10/18/2024
Gastroenterology
News
Repeat FIT Offers Greater Differentiation of Patients With, Without Significant Pathology
10/09/2024
Conducting repeat fecal immunochemical tests doubled the detection rates of colorectal cancer and significant bowel disease, researchers reported.
Conducting repeat fecal immunochemical tests doubled the detection rates of colorectal cancer and significant bowel disease, researchers reported.
Conducting repeat fecal...
10/09/2024
Gastroenterology
News
AI-Enabled Electrocardiogram Shows Promise in Predicting MASLD
10/08/2024
Researchers explored the use of an artificial intelligence model to detect metabolic dysfunction–associated steatotic liver disease.
Researchers explored the use of an artificial intelligence model to detect metabolic dysfunction–associated steatotic liver disease.
Researchers explored the use of...
10/08/2024
Gastroenterology
News
FDA Approves Cologuard Plus
10/07/2024
The U.S. Food and Drug Administration (FDA) on October 4 approved the Cologuard Plus multitarget stool DNA test for adults ages 45 and older who are average risk for colorectal cancer.
The U.S. Food and Drug Administration (FDA) on October 4 approved the Cologuard Plus multitarget stool DNA test for adults ages 45 and older who are average risk for colorectal cancer.
The U.S. Food and Drug...
10/07/2024
Gastroenterology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use